>>AB-CHMINACA metabolite M6

AB-CHMINACA metabolite M6

Catalog No.GC40647

AB-CHMINACA is a cyclohexyl-substituted derivative of the indazole-based synthetic cannabinoid, AB-FUBINACA.

Products are for research use only. Not for human use. We do not sell to patients.

AB-CHMINACA metabolite M6 Chemical Structure

Size 가격 재고 수량
500μg
US$163.00
재고 있음
1mg
US$310.00
재고 있음
5mg
US$1,302.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AB-CHMINACA is a cyclohexyl-substituted derivative of the indazole-based synthetic cannabinoid, AB-FUBINACA [1] [2]. AB-CHMINACA metabolite M6 is a potential metabolite in which the carboxamide-linked aminocarbonyl-2-methylpropyl side chain associated with both AB-CHMINACA and AB-FUBINACA features an additional carboxyl group. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications.

Reference:
[1]. Uchiyama, N., Matsuda, S., Wakana, D., et al. New cannabimimetic indazole derivatives, N-(1-amino-3methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol. 31(1), 93-100 (2013).
[2]. Buchler, I.P., Hayes, M.J., Hedge, S.G., et al. Indazole derivatives. 1-283 (2009).

리뷰

Review for AB-CHMINACA metabolite M6

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AB-CHMINACA metabolite M6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.